Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Lung Neoplasms 83Lymphoma 76Head and Neck Neoplasms 76Glioblastoma 75Squamous Cell Carcinoma of Head and Neck 71Breast Neoplasms 71Rectal Neoplasms 67Esophageal Neoplasms 63Prostatic Neoplasms 59Leukemia 57Central Nervous System Neoplasms 54Pancreatic Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 43Lymphoma, Large B-Cell, Diffuse 43Hodgkin Disease 42Lymphoma, Follicular 41Brain Neoplasms 40Leukemia, Lymphocytic, Chronic, B-Cell 39Esophageal Squamous Cell Carcinoma 39Colorectal Neoplasms 38Burkitt Lymphoma 37Gliosarcoma 36Lymphoma, Large-Cell, Immunoblastic 33Uterine Cervical Neoplasms 31Neoplasms 31Adenocarcinoma Of Esophagus 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 29

Interventions

tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muscle-invasive Bladder Cancer × Radiotherapy × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡